Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Pulse oximetry screening (POS) for critical congenital heart defects (CCHD) has consistent test accuracy,1 meets the criteria for a universal screening test1 and reduces mortality.2
In May 2019, the National Screening Committee (NSC) announced a public consultation on its decision not to introduce routine POS for CCHD in all newborn babies.1
The main reasons given for the NSC’s decision are outlined in the consultation cover note as follows:
‘A positive result from pulse oximetry will generate some harms, including parental anxiety, a longer stay in hospital, possible transfer to the neonatal unit (NNU), further tests to assess for non-symptomatic conditions.
For many of these babies, further investigations will be unnecessary and the baby will be identified as healthy. This is a false positive result.
For babies with CHD (congenital heart defects) or other non-cardiac condition, it is not clear that investigations and identification of these conditions will …
Contributors AKE wrote the first draft. All authors edited and approved subsequent drafts.
Competing interests AKE was a clinical adviser to the NSC regarding POS and the clinical lead on the PHE pulse oximetry pilot. SAD is Hon. Treasurer, British Association of Perinatal Medicine (BAPM). MU is Patient Safety Lead for NHS England,CE was project lead for the PHE pulse oximetry pilot. SJO is the Clinical Lead for the National Neonatal Audit Project (NNAP).
Provenance and peer review Not commissioned; internally peer reviewed.
Patient consent for publication Not required.